

UNITED STATES PATENT APPLICATION

Fc fusion proteins of human erythropoietin with increased biological activities

Inventors:

Lee-Hwei K. Sun, Bill N. C. Sun, and Cecily R. Y. Sun

Certificate of Mailing under 37 CFR 1.10

I hereby that this correspondence is being deposited with the United States Postal Service with sufficient postage as express mail in an envelope addressed to:


Commissioner for Patents

Washington, D.C. 20231

Express Mail Label No. EE 14 235 123 545

Date August 17, 2001

Hsiang-ning Sun



Fc fusion proteins of human erythropoietin with increased biological activities

Inventors: Lee-Hwei K. Sun, Bill N. C. Sun, and Cecily R. Y. Sun

5 **Background**

[0001] Erythropoietin (EPO) is a 30.4 kilodalton (kDa) glycoprotein hormone that promotes the proliferation of erythroid progenitor cells and supports their differentiation into mature erythrocytes (see, for example, Krantz, *Blood*, 77:419-434, 10 1991). EPO is produced in the adult kidney and the fetal liver. In adults, EPO is produced primarily in kidney cells in response to hypoxia or anemia and circulates in the bloodstream. EPO targets the 66 kDa specific receptor (EPO-Rc) found almost exclusively on the surface of erythroid progenitor cells present in bone marrow. Upon binding EPO, the receptor is activated and undergoes homodimerization, followed by 15 tyrosine phosphorylation. Subsequently, a series of intracellular signal transduction events take place, leading to the increase of the number of the progenitor cells and their maturation into erythrocytes (see, for example, Lodish et al., *Cold Spring Harbor Symp. Quant. Biol.*, 60:93-104, 1995).

[0002] Recombinant human EPO (rHuEPO) is widely used in the treatment of patients with chronic anemia due to renal diseases at both end-stage and pre-dialysis phases. Administration of EPO has also been successful to treat anemia in patients caused by cancer chemotherapy, rheumatoid arthritis, AZT treatment for HIV infection and myelodysplastic syndrome. No direct toxic effect of treatment has been 20 reported and the benefits of blood transfusion could be achieved without the transfusion.

[0003] The concentration of EPO in normal human serum varies approximately from 0.01 to 0.03 units/ml. Supplemental EPO is a desirable treatment in cases of renal failure with decreased EPO production. The half-life for the serum clearance of intravenous (i.v.) rHuEPO is approximately 4 to 13 h. The peak serum 30 concentration for subcutaneous (s.c.) rHuEPO occurs in 5 to 24 h after injection with an elimination half-life of 17 h. The s.c. administration route can therefore lead to much

longer retention in the blood than i.v. administration of the same dose. The mechanism responsible for clearing EPO from the serum remains unclear. In animal experiments, less than 5% is excreted by the kidney. The liver, which rapidly removes asialated EPO, has not been shown to play a significant role in clearing EPO (see, for example, Fried, 5 *Annu. Rev. Nutr.*, 15:353-377, 1995).

[0004] Immunoglobulins of IgG class are among the most abundant proteins in human blood. Their circulation half-lives can reach as long as 21 days. Fusion proteins have been reported to combine the Fc regions of IgG with the domains of 10 another protein, such as various cytokines and soluble receptors (see, for example, Capon et al., *Nature*, 337:525-531, 1989; Chamow et al., *Trends Biotechnol.*, 14:52-60, 1996); US patents 5,116,964 and 5,541,087). The prototype fusion protein is a homodimeric protein linked through cysteine residues in the hinge region of IgG Fc, resulting in a molecule similar to an IgG molecule without the CH1 domains and light chains. Due to 15 the structural homology, Fc fusion proteins exhibit *in vivo* pharmacokinetic profile comparable to that of human IgG with a similar isotype. This approach has been applied to several therapeutically important cytokines, such as IL-2 and IFN- α_{2a} , and soluble receptors, such as TNF-Rc and IL-5-Rc (see, for example, US patents 5,349,053 and 6,224,867). To extend the circulating half-life of EPO and/or to increase its biological 20 activity, it is desirable to make fusion proteins containing EPO linked to the Fc portion of the human IgG protein as disclosed or described in this invention.

[0005] In most of the reported Fc fusion protein molecules, a hinge region serves as a spacer between the Fc region and the cytokine or soluble receptor at the 25 amino-terminus, allowing these two parts of the molecule to function separately (see, for example, Ashkenazi et al., *Current Opinion in Immunology*, 9:195-200, 1997). Relative to the EPO monomer, a fusion protein consisting of two complete EPO domains separated by a 3- to 7-amino acid peptide linker exhibited reduced activity (Qiu et al., *J. Biol. Chem.*, 273:11173-11176, 1998). However, when the peptide linker between the 30 two EPO domains was 17 amino acids in length, the dimeric EPO molecule exhibited considerably enhanced *in vitro* and *in vivo* activities. The enhanced activity has been shown to be due to an increased *in vitro* activity coupled with a different

pharmacokinetic profile in mice (see, for example, Sytkowski et al., *J. Biol. Chem.*, 274:24773-24778, 1999; US patent 6,187,564). A human EPO fusion protein with an appropriate peptide linker between the HuEPO and Fc moieties (HuEPO-L-Fc) is more active than rHuEPO, with *in vitro* activity at least 2-fold as that of rHuEPO on a molar basis. It is discovered according to this invention that an added peptide linker present between HuEPO and a human IgG Fc variant enhances the *in vitro* biological activity of the HuEPO-L-Fc molecule in two ways: (1) keeping the Fc region away from the EPO-Rc binding sites on EPO, and (2) keeping one EPO from the other EPO domain, so both EPO domains can interact with EPO-Rc on the erythroid progenitor cells independently. For the present invention, a flexible peptide linker of about 20 or fewer amino acids in length is preferred. It is preferably to use a peptide linker comprising of two or more of the following amino acids: glycine, serine, alanine, and threonine.

[0006] The Fc region of human immunoglobulins plays a significant role in immune defense for the elimination of pathogens. Effector functions of IgG are mediated by the Fc region through two major mechanisms: (1) binding to the cell surface Fc receptors (Fc_γRs) can lead to ingestion of pathogens by phagocytosis or lysis by killer cells *via* the antibody-dependent cellular cytotoxicity (ADCC) pathway, or (2) binding to the C1q part of the first complement component C1 initiates the complement-dependent cytotoxicity (CDC) pathway, resulting in the lysis of pathogens. Among the four human IgG isotypes, IgG1 and IgG3 are effective in binding to Fc_γR. The binding affinity of IgG4 to Fc_γR is an order of magnitude lower than that of IgG1 or IgG3, while binding of IgG2 to Fc_γR is below detection. Human IgG1 and IgG3 are also effective in binding to C1q and activating the complement cascade. Human IgG2 fixes complement poorly, and IgG4 appears quite deficient in the ability to activate the complement cascade (see, for example, Jefferis et al., *Immunol. Rev.*, 163:59-76, 1998). For therapeutic use in humans, it is essential that when HuEPO-L-Fc binds to EPO-Rc on the surface of the erythroid progenitor cells, the Fc region of the fusion protein will not mediate undesirable effector functions, leading to the lysis or removal of these progenitor cells. Accordingly, the Fc region of HuEPO-L-Fc must be of a non-lytic nature, *i. e.* the Fc region must be inert in terms of binding to Fc_γRs and C1q for the triggering of effector functions. It is clear that none of the naturally occurring IgG isotypes is suitable for use

to produce the HuEPO-L-Fc fusion protein. To obtain a non-lytic Fc, certain amino acids of the natural Fc region have to be mutated for the attenuation of the effector functions.

5 [0007] By comparing amino acid sequences of human and murine IgG isotypes, a portion of Fc near the N-terminal end of the CH2 domain is implicated to play a role in the binding of IgG Fc to Fc γ Rs. The importance of a motif at positions 234 to 237 has been demonstrated using genetically engineered antibodies (see, for example, Duncan et al., *Nature*, 332:563-564, 1988). The numbering of the amino acid residues is
10 according to the EU index as described in Kabat et al. (in *Sequences of Proteins of Immunological Interest*, 5th Edition, United States Department of Health and Human Services, 1991). Among the four human IgG isotypes, IgG1 and IgG3 bind Fc γ Rs the best and share the sequence Leu234-Leu-Gly-Gly237 (only IgG1 is shown in Figure 1). In IgG4, which binds Fc γ Rs with a lower affinity, this sequence contains a single amino
15 acid substitution, Phe for Leu at position 234. In IgG2, which does not bind Fc γ Rs, there are two substitutions and a deletion leading to Val234-Ala-Gly237 (Figure 1). To minimize the binding of Fc to Fc γ R and hence the ADCC activity, Leu235 in IgG4 has been replaced by Ala (see, for example, Hutchins et al., *Proc. Natl. Acad. Sci. USA*, 92:11980-11984, 1995). IgG1 has been altered in this motif by replacing Glu233-Leu-
20 Leu235 with Pro233-Val-Ala235, which is the sequence from IgG2. This substitution resulted in an IgG1 variant devoid of Fc γ R-mediated ability to deplete target cells in mice (see, for example, Isaacs et al., *J. Immunol.*, 161: 3862-3869, 1998).

 [0008] A second portion that appears to be important for both Fc γ R and
25 C1q binding is located near the carboxyl-terminal end of CH2 domain of human IgG (see, for example, Duncan et al., *Nature*, 332:738-740, 1988). Among the four human IgG isotypes, there is only one site within this portion that shows substitutions: Ser330 and Ser331 in IgG4 replacing Ala330 and Pro331 present in IgG1, IgG2, and IgG3 (Figure 1). The presence of Ser330 does not affect the binding to Fc γ R or C1q. The
30 replacement of Pro331 in IgG1 by Ser virtually abolished IgG1 ability to C1q binding, while the replacement of Ser331 by Pro partially restored the complement fixation

activity of IgG4 (see, for example, Tao et al., *J. Exp. Med.*, 178:661-667, 1993; Xu et al., *J. Biol. Chem.*, 269:3469-3474, 1994).

[0009] We discover that at least three Fc variants (vFc) can be designed for the production of HuEPO-L-vFc fusion proteins (Figure 1). Human IgG2 Fc does not bind Fc_γR but showed weak complement activity. An Fc_{γ2} variant with Pro331Ser mutation should have less complement activity than natural Fc_{γ2} while remain as a non-binder to Fc_γR. IgG4 Fc is deficient in activating the complement cascade, and its binding affinity to Fc_γR is about an order of magnitude lower than that of the most active isotype, IgG1. An Fc_{γ4} variant with Leu235Ala mutation should exhibit minimal effector functions as compared to the natural Fc_{γ4}. The Fc_{γ1} variant with Leu234Val, Leu235Ala and Pro331Ser mutations also will exhibit much less effector functions than the natural Fc_{γ1}. These Fc variants are more suitable for the preparation of the EPO fusion proteins than naturally occurring human IgG Fc. It is possible that other replacements can be introduced for the preparation of a non-lytic Fc without compromising the circulating half-life or causing any undesirable conformational changes.

[0010] There are many advantages with the present invention. The increased activity and prolonged presence of the HuEPO-L-vFc fusion protein in the serum can lead to lower dosages as well as less frequent injections. Less fluctuations of the drug in serum concentrations also means improved safety and tolerability. Less frequent injections may result in better patient compliance and quality of life. The HuEPO-L-vFc fusion protein containing a non-lytic Fc variant will therefore contribute significantly to the management of anemia caused by conditions including renal failure, cancer chemotherapy, rheumatoid arthritis, AZT treatment for HIV infection, and myelodysplastic syndrome.

Summary of the invention

[0011] One aspect of the present invention relates to a HuEPO-L-vFc fusion protein. The HuEPO-L-vFc fusion protein comprises HuEPO, a peptide linker, and a human IgG Fc variant. It is preferably to use a flexible peptide linker of 20 or

fewer amino acids in length which comprises of two or more of the following amino acids: glycine, serine, alanine, and threonine. The IgG Fc variant is of non-lytic nature and contains amino acid mutations as compared to naturally occurring IgG Fc.

5 [0012] It is another embodiment of the present invention that the human Ig Fc comprises a hinge, CH2, and CH3 domains of human IgG, such as human IgG1, IgG2, and IgG4. The CH2 domain contains amino acid mutations at positions 228, 234, 235, and 331 (defined by the EU numbering system) to attenuate the effector functions of Fc.

10

 [0013] In yet another embodiment of the present invention, a method is disclosed to make or produce such fusion proteins from a mammalian cell line such as a CHO-derived cell line. Growing transfected cell lines under conditions such that the recombinant fusion protein is expressed in its growth medium in excess of 10, preferably
15 30, µg per million cells in a 24 hour period. These HuEPO-L-vFc fusion proteins exhibit increased biological activity and extended serum half-life without undesirable side effects, leading to improved pharmacokinetics and pharmacodynamics, thus lower dosages and fewer injections would be needed to achieve similar efficacies.

20 **Brief descriptions of the drawings**

 [0014] Figure 1 shows the amino acid sequence alignment from the hinge and CH2 regions of human IgG1, IgG2, IgG4 and their variants. Three portions are compared: amino acid position 228, 234-237, and 330-331. Amino acid mutations of the
25 variants are indicated in bold italics. The EU numbering system is used for the amino acid residues.

 [0015] Figure 2 shows the nucleotide sequence and deduced amino acid sequence of (A) HuEPO-L-vFc_{γ2}, (B) HuEPO-L-vFc_{γ4}, and (C) HuEPO-L-vFc_{γ1} as the
30 *HindIII-EcoRI* fragment in the respective pEFP expression vector. The peptide from amino acid residues -27 to -1 is the leader peptide of human EPO. The mature protein contains human EPO (amino acid residues 1 to 165), a peptide linker (amino acid

residues 166 to 181), and a Fc variant (amino acid residues 182 to 409 of vFc_{γ2}, 182 to 410 of vFc_{γ4}, and 182 to 408 of vFc_{γ1}). In the Fc regions, nucleotide and corresponding amino acid mutations in bold are also underlined.

5 Detailed description of the invention

1. Construction of the gene encoding the HuEPO-L-vFc_{γ2} fusion protein

[0016] A fusion protein is assembled from several DNA segments. To obtain the gene encoding the leader peptide and mature protein of human EPO, cDNA library of human fetal liver or kidney (obtained from Invitrogen, Carlsbad, CA) is used as the template in polymerase chain reaction (PCR). For the convenience of cloning, SEQ ID NO:1 (Table 1), which incorporates a restriction enzyme cleavage site (*Hind*III) is used as the 5' oligonucleotide primer. Table 1 shows the sequences of oligonucleotides used for the cloning of the HuEPO-L-vFc fusion proteins. The 3' primer (SEQ ID NO:2) eliminates the EPO termination codon and incorporates a *Bam*HI site. The resulting DNA fragments of approximately 600 bp in length are inserted into a holding vector such as pUC19 at the *Hind*III and *Bam*HI sites to give the pEPO plasmid. The sequence of the human EPO gene is confirmed by DNA sequencing.

[0017] The gene encoding the Fc region of human IgG2 (Fc_{γ2}) is obtained by reverse transcription and PCR using RNA prepared from human leukocytes and appropriate 5' (SEQ ID NO:3) and 3' (SEQ ID NO:4) primers. Resulting DNA fragments of Fc_{γ2} containing complete sequences of the hinge, CH2, and CH3 domains of IgG2 will be used as the template to generate the Fc_{γ2} Pro331Ser variant (vFc_{γ2}) in which Pro at position 331 of Fc_{γ2} is replaced with Ser. To incorporate this mutation, two segments are produced and then assembled by using the natural Fc_{γ2} as the template in overlapping PCR. The 5' segment is generated by using SEQ ID NO:3 as the 5' primer and SEQ ID NO:5 as the 3' primer. The 3' segment is generated by using SEQ ID NO:6 as the 5' primer and SEQ ID NO:4 as the 3' primer. These two segments are then joined at the region covering the Pro331Ser mutation by using SEQ ID NO:7 as the 5' primer and SEQ ID NO:4 as the 3' primer.

The SEQ ID NO:7 primer contains sequences encoding a 16-amino acid Gly-Ser peptide linker including a *Bam*HI restriction enzyme site. The resulting DNA fragments of approximately 700 bp in length are inserted into a holding vector such as pUC19 at the *Bam*HI and *Eco*RI sites to give the pL-vFc γ 2 plasmid. The sequence of the gene is confirmed by DNA sequencing.

[0018] To prepare the HuEPO-L-vFc γ 2 fusion gene, the EPO fragment is excised from the pEPO plasmid with *Hind*III and *Bam*HI and is purified by agarose gel electrophoresis. The purified fragment is then inserted to the 5'-end of the peptide linker in the pL-vFc γ 2 plasmid to give the pEPO-L-vFc γ 2 plasmid. The fusion gene comprises HuEPO, a Gly-Ser peptide linker and the Fc γ 2 variant gene.

[0019] The presence of a peptide linker between the EPO and Fc moieties increases the flexibility of the EPO domains and enhances its biological activity (see, for example, Sytkowski et al., *J. Biol. Chem.*, 274: 24773-8, 1999). For the present invention, a peptide linker of about 20 or fewer amino acids in length is preferred. Peptide linker comprising two or more of the following amino acids: glycine, serine, alanine, and threonine can be used. An example of the peptide linker contains Gly-Ser peptide building blocks, such as GlyGlyGlyGlySer. Figure 2A shows a fusion gene containing sequences encoding HuEPO, a 16-amino acid peptide linker (GlySerGlyGlyGlySerGlyGlyGlyGlySerGlyGlyGlyGlySer), and the Fc γ 2 Pro331Ser variant.

[0020] The complete gene encoding the HuEPO-L-vFc fusion protein is then inserted at the *Hind*III and *Eco*RI sites of a mammalian expression vector, such as pcDNA3 (Invitrogen). The final expression vector plasmid, named pEFP2, contains the cytomegalovirus early gene promoter-enhancer which is required for high level expression in mammalian cells. The plasmid also contains selectable markers to confer ampicillin resistance in bacteria, and G418 resistance in mammalian cells. In addition, the pEFP2 expression vector contains the dihydrofolate reductase (DHFR) gene to enable the co-amplification of the HuEPO-L-vFc γ 2 fusion gene and the DHFR gene in the presence of methotrexate (MTX)

when the host cells are deficient in the DHFR gene expression (see, for example, US patent 4,399,216).

2. Construction of the gene encoding the HuEPO-L-vFc_{γ4} fusion protein

[0021] Human IgG4 is observed partly as half antibody molecules due to the dissociation of the inter-heavy chain disulfide bonds in the hinge domain. This is not seen in the other three human IgG isotypes. A single amino acid substitution replacing Ser228 with Pro, which is the residue found at this position in IgG1 and IgG2, leads to the formation of IgG4 complete antibody molecules (see, for example, Angal et al., *Molec. Immunol.*, 30:105-108, 1993; Owens et al., *Immunotechnology*, 3:107-116, 1997; US Patent 6,204,007). The Fc_{γ4} variant containing Leu235Ala mutation for the minimization of FcR binding will also give rise to a homogeneous fusion protein preparation with this additional Ser228Pro mutation.

[0022] The gene encoding the Fc region of human IgG4 (Fc_{γ4}) is obtained by reverse transcription and PCR using RNA prepared from human leukocytes and appropriate 5' primer (SEQ ID NO:8) and 3' primer (SEQ ID NO:9). Resulting DNA fragments of Fc_{γ4} containing complete sequences of the hinge, CH2, and CH3 domains of IgG4 is used as the template to generate the Fc_{γ4} variant with Ser228Pro and Leu235Ala mutations (vFc_{γ4}) in which Ser228 and Leu235 have been replaced with Pro and Ala, respectively. The CH2 and CH3 domains are amplified using the 3' primer (SEQ ID NO:9) and a 5' primer containing the Leu235Ala mutation (SEQ ID NO:10). This amplified fragment, together with a synthetic oligonucleotide of 60 bases in length (SEQ ID NO:11) containing both Ser228Pro and Leu235Ala mutations, are joined in PCR by using SEQ ID NO:12 as the 5' primer and SEQ ID NO:9 as the 3' primer. The SEQ ID NO:12 primer contains sequences encoding a 16-amino acid Gly-Ser peptide linker including the *Bam*HI site. The resulting DNA fragments of approximately 700 bp in length are inserted into a holding vector such as pUC19 at the *Bam*HI and *Eco*RI sites to give the pL-vFc_{γ4} plasmid. The sequence of the gene is confirmed by DNA sequencing.

[0023] To prepare the HuEPO-L-vFc_{γ4} fusion gene, the HuEPO fragment is excised from the pEPO plasmid with *Hind*III and *Bam*HI and then inserted to the 5'-end of the peptide linker in the pL-vFc_{γ4} plasmid to give the pEPO-L-vFc_{γ4} plasmid. This fusion gene comprising HuEPO, a 16-amino acid Gly-Ser peptide linker and the Fc_{γ4} variant gene is then inserted at the *Hind*III and *Eco*RI sites of a mammalian expression vector, such as pcDNA3 (Invitrogen), as described for the HuEPO-L-vFc_{γ2} fusion protein. The final expression vector plasmid is designated as pEFP4. Figure 2B shows a fusion gene containing sequences encoding HuEPO, a 16-amino acid peptide linker (GlySerGlyGlyGlySerGlyGlyGlyGlySerGlyGlyGlyGlySer), and the Fc_{γ4} variant with Ser228Pro and Leu235Ala mutations.

3. Construction of the gene encoding the HuEPO-L-vFc_{γ1} fusion protein

[0024] The hinge domain of human IgG1 heavy chain contains 15 amino acid residues (GluProLysSerCysAspLysThrHisThrCysProProCysPro) including 3 cysteine residues. Out of these 3 cysteine residues, the 2nd and 3rd are involved in the formation of disulfide bonding between two heavy chains. The 1st cysteine residue is involved in the disulfide bonding to the light chain of IgG. Since there is no light chain present in the Fc fusion protein molecule, this cysteine residue may pair with other cysteine residues, leading to nonspecific disulfide bonding. The hinge domain of Fc_{γ1} can be truncated to eliminate the 1st cysteine residue (AspLysThrHisThrCysProProCysPro). The gene encoding the Fc_{γ1} region is obtained by reverse transcription and PCR using RNA prepared from human leukocytes and appropriate 5' primer (SEQ ID NO:13) and 3' primer (SEQ ID NO:4). Resulting DNA fragments containing the truncated hinge and complete sequences of CH2 and CH3 domains of Fc_{γ1} is used as the template to generate the Fc_{γ1} variant with Leu234Val, Leu235Ala, and Pro331Ser mutations (vFc_{γ1}).

[0025] One way to incorporate these mutations is as follows: two segments are produced and then assembled by using the natural Fc_{γ1} as the template in overlapping PCR. The 5' segment is generated by using SEQ ID NO:14 as the 5'

primer and SEQ ID NO:5 as the 3' primer. This 5' primer contains the Leu234Val, Leu235Ala mutations and the 3' primer contains the Pro331Ser mutation. The 3' segment is generated by using SEQ ID NO:6 as the 5' primer and SEQ ID NO:4 as the 3' primer. These 5' and 3' segments are then joined at the region covering the Pro331Ser mutation by using SEQ ID NO:14 as the 5' primer and SEQ ID NO:4 as the 3' primer. This amplified fragment of approximately 650 bp in length, together with a synthetic oligonucleotide of 55 bases (SEQ ID NO:15) containing Leu234Val and Leu235Ala, are joined in PCR by using SEQ ID NO:16 as the 5' primer and SEQ ID NO:4 as the 3' primer. The SEQ ID NO:16 primer contains sequences encoding a 16-amino acid Gly-Ser peptide linker including the *Bam*HI site. The resulting DNA fragments of approximately 700 bp in length are inserted into a holding vector such as pUC19 at the *Bam*HI and *Eco*RI sites to give the pL-vFc_γ1 plasmid. The sequence of the gene is confirmed by DNA sequencing.

[0026] To prepare the HuEPO-L-vFc_γ1 fusion gene, the EPO fragment is excised from the pEPO plasmid with *Hind*III and *Bam*HI and inserted to the 5'-end of the peptide linker in the pL-vFc_γ1 plasmid to give the pEPO-L-vFc_γ1 plasmid. The fusion gene comprising HuEPO, a 16-amino acid Gly-Ser peptide linker, and the Fc_γ1 variant gene is then inserted at the *Hind*III and *Eco*RI sites of a mammalian expression vector, such as pcDNA3 (Invitrogen), as described for the HuEPO-L-vFc_γ2 fusion protein. The final expression vector plasmid is designated as pEFP1. Figure 2C shows a fusion gene containing sequences encoding HuEPO, a 16-amino acid peptide linker (GlySerGlyGlyGlySerGlyGlyGlyGlySerGlyGlyGlyGlySer), and the Fc_γ1 variant with Leu234Val, Leu235Ala and Pro331Ser mutations.

4. Expression of the fusion protein in transfected cell lines

[0027] The recombinant pEFP1, pEFP2 or pEFP4 expression vector plasmid is transfected into a mammalian host cell line to achieve the expression of the HuEPO-L-vFc fusion protein. For stable high levels of expression, a preferred host cell line is Chinese Hamster Ovary (CHO) cells deficient in the DHFR enzyme (see, for example, US patent 4,818,679). A preferred method of transfection is

electroporation. Other methods, including calcium phosphate co-precipitation, lipofectin, and protoplast fusion, can also be used. For electroporation, 10 µg of plasmid DNA linearized with *Bsp*CI is added to 2 to 5 x 10⁷ cells in a cuvette using Gene Pulser Electroporator (Bio-Rad Laboratories, Hercules, CA) set at an electric field of 250 V and a capacitance of 960 µFd. Two days following the transfection, the media are replaced with growth media containing 0.8 mg/ml of G418. Transfectants resistant to the selection drug are tested for the secretion of the fusion protein by anti-human IgG Fc ELISA. Quantitation of the expressed fusion protein can also be carried out by ELISA using anti-HuEPO assays. The wells producing high levels of the Fc fusion protein are subcloned by limiting dilutions on 96-well tissue culture plates.

[0028] To achieve higher levels of the fusion protein expression, co-amplification is preferred by utilizing the gene of DHFR which can be inhibited by the MTX drug. In growth media containing increasing concentrations of MTX, the transfected fusion protein gene is co-amplified with the DHFR gene. Transfectants capable of growing in media with up to 1 µg/ml of MTX are again subcloned by limiting dilutions. The subcloned cell lines are further analyzed by measuring the secretion rates. Several cell lines yielding secretion rate levels over about 10, preferably about 30 µg/10⁶ cells/24h, are adapted to suspension culture using serum-free growth media. The conditioned media are then used for the purification of the fusion protein.

[0029] Sugar side chain structures are crucial for the *in vivo* activity of EPO. The terminal sugar chain of the Asn-linked carbohydrate contains sialic acids, repeating poly-N-acetylactosamine and galactose. Recombinant HuEPO expressed in certain mammalian cells such as NS0 is known to give proteins with low sialic acid content. Removal of sialic acids, which leads to exposure of the penultimate galactose residues, increases the affinity for hepatic asialoglycoprotein binding lectin. This trapping pathway results in decrease of *in vivo* biological activity as measured in whole animals. Recombinant HuEPO produced in CHO cells exhibit glycosylation patterns very similar to that found in the natural EPO (see, for example, Takeuchi et

al., *Proc. Natl. Acad. Sci. USA*, 86:7819-22, 1989). The HuEPO-L-vFc fusion proteins expressed and produced in accordance with this invention will show enhanced biological activities when compared to rHuEPO on a molar basis.

5 5. Purification and characterization of the fusion protein

[0030] Conditioned media containing the fusion protein are titrated with 1 N NaOH to a pH of 7 to 8 and filtered through a 0.45 micron cellulose nitrate filter. The filtrate is loaded onto a Prosep A column equilibrated in phosphate-buffered saline (PBS). After binding of the fusion protein to Prosep A, the flow-through fractions are discarded. The column is washed with PBS until OD at 280 nm is below 0.01. The bound fusion protein is then eluted with 0.1 M citrate buffer at pH 3.75. After neutralizing with 0.4 volume of 1 M K₂HPO₄, fractions containing purified protein are pooled and dialyzed against PBS. The solution is then filtered through a 0.22 micron cellulose nitrate filter and stored at 4°C. The molecular weight of purified HuEPO-L-vFc protein is in the range of 110 and 130 kDa by SDS-PAGE under non-reducing conditions. Under reducing conditions, the purified protein migrates around approximately 60 kDa. The fusion protein is quantitated by BCA protein assay using BSA as the standard.

20 6. In vitro biological assays

[0031] Supernatants of transfectants or purified proteins can be tested for their ability to stimulate the proliferation of TF-1 cells (Kitamura et al., *J. Cell. Physiol.*, 140:323-334, 1989). TF-1 cells naturally express human EPO-Rc on their cell surface and are responsive to EPO. The cells are maintained in growth medium (RPMI-1640 medium containing 10% FCS and human IL-5 at 1 to 5 ng/ml). Log phase TF-1 cells are collected and washed with assay medium (growth medium without human IL-5). A total of 1×10^4 cells per sample of TF-1 in 50 µl is added to each well of a 96-well tissue culture plate. The cells are incubated with 50 µl of assay media containing various concentrations of the HuEPO-L-vFc fusion protein or the rHuEPO control from 0.01 to 100 nM each. The plate is kept at 37°C and 5%

CO₂ in a humidified incubator for 4 days before 10 µl of MTT (2.5 mg/ml in PBS) is added to each well. After 4 h, the cells and formazan are solubilized by adding 100µl per well of 10% SDS in 0.01 N HCl. The plate is then read at 550 nm with the reference beam set at 690 nm. The OD reading is plotted against the concentration of rHuEPO or the fusion protein. The inflection point of the sigmoidal curve represents the concentration at which 50% of the maximal effect, ED₅₀, is induced. The biological activity of HuEPO-L-vFc relative to that of rHuEPO can therefore be compared quantitatively. Preferably, the fusion proteins should exhibit an enhanced activity of at least 2 fold relative to that of rHuEPO on a molar basis. In one embodiment of the present invention, the specific activity of the HuEPO-L-vFc fusion protein is in the range of about 6 to about 8 x 10⁶ units/µmole, compared to about 3 to about 4 x 10⁶ units/µmole for rHuEPO.

[0032] Supernatants of transfectants or purified proteins can also be tested for their ability to stimulate the proliferation and differentiation of human bone marrow progenitor cells to form red blood cell colonies, colony forming unit-erythroid (CFU-E). The procedure is as follows. Light-density cells from human bone marrow centrifuged over Ficoll-Paque are washed and resuspended at 1 x 10⁶ cells/ml in Iscove's modified Dulbecco's medium (IMDM) containing 5% FCS. These cells are incubated in a tissue culture dish overnight at 37°C and 5% CO₂ to remove all adherent cells including monocytes, macrophages, endothelial cell, and fibroblasts. Cells in suspension are then adjusted to 1 x 10⁵ cells/ml in IMDM containing 5% FCS. For the assay, 0.3 ml of cells, 15 µl of stem cell factor at 20 µg/ml, 2.4 ml of methylcellulose, and 0.3 ml of media containing several concentrations of HuEPO-L-vFc (or rHuEPO control) are mixed. One ml of this cell mixture is plated on a 35-mm petri dish. The dishes are then kept at 37°C and 5% CO₂ for 10 to 14 d before the colonies are counted. A dose responsive curve can be plotted against the concentrations of HuEPO-L-vFc relative to those of rHuEPO.

7. In vivo pharmacokinetic studies in rats

[0033] Fisher rats (Harlan Bioproducts for Science, Indianapolis, IN) with an average body weight of about 500 g are injected i.v. through the tail vein or s.c. with 100 units of rHuEPO or the HuEPO-L-vFc fusion protein. An equal volume of PBS is injected as a control. Serial 0.5-ml samples are taken through retro-orbital
5 bleeds at different points (0, 0.2, 1, 4, 24, 48, 96, and 168 h) after injection. There are 3 rats for each time point. Whole blood is collected into tubes containing anticoagulant, cells are removed, and plasma is frozen at -70°C until assay is carried out.

10 [0034] Serum samples are used for TF-1 cell assays, which measure the activity of EPO-mediated cell proliferation. A total of 1×10^4 cells per sample of TF-1 in 50 μ l is added to each well of a 96-well tissue culture plate. The cells are incubated with 50 μ l of assay media containing various concentrations of titrated blood samples. The plate is kept at 37°C and 5% CO₂ in a humidified incubator for 4
15 days. Viable cells are stained with 10 μ l of MTT (2.5 mg/ml in PBS). After 4 h, the cells and formazan are solubilized by adding 100 μ l per well of 10% SDS in 0.01 N HCl. The plate is then read at 550 nm with the reference beam set at 690 nm. The activities of serum samples are plotted against time points for the calculation of the circulation time. The activity of HuEPO-L-vFc decreases much slower than that of
20 the rHuEPO control, indicating the longer circulating half-life of the fusion protein in rats.

[0035] The examples described above are for illustration purposes only. They are not intended and should not be interpreted to limit either the scope or the
25 spirit of this invention. It can be appreciated by those skilled in the art that many other variations or substitutes can be used as equivalents for the purposes of this invention, which is defined solely by the written description and the following claims.

Table 1. Sequences of Oligonucleotides.

	SEQ ID NO:1
5	5'-cccaagcttggcgcgagatgggggtgca-3'
	SEQ ID NO:2
	5'-cggatccgtcccctgtcctgcaggcct-3'
10	SEQ ID NO:3
	5'-gagcgcaaattgtgtgtcga-3'
	SEQ ID NO:4
	5'-ggaattctcatttaccgcgagacaggga-3'
15	SEQ ID NO:5
	5'-tggttttctcgatggaggctgggaggcct-3'
	SEQ ID NO:6
20	5'-aggcctcccagcctccatcgagaaaacca-3'
	SEQ ID NO:7
	5'-cggatccggtggcggttccggtggaggcggaagcggcggtggaggatcag agcgcaaattgtgtgtcga-3'
25	SEQ ID NO:8
	5'-gagtccaaatatggtcccca-3'
	SEQ ID NO:9
	5'-ggaattctcatttaccagagacaggga-3'
30	SEQ ID NO:10
	5'-cctgagttcgcggggggacca-3'
	SEQ ID NO:11
35	5'-gagtccaaatatggtcccccattgccaccatgccagcacctgagttcgcgg gggacca-3'
	SEQ ID NO:12
40	5'-cggatccggtggcggttccggtggaggcggaagcggcggtggaggatcagag tccaaatatggtcccca-3'
	SEQ ID NO:13
	5'-gacaaaactcacacatgccca-3'
45	SEQ ID NO:14
	5'-acctgaagtcgcggggggaccgt-3'

SEQ ID NO:15

5'-gacaaaactcacacatgccaccgtgccagcacctgaagtcgcggggggac
cgt -3'

5

SEQ ID NO:16

5'-cggatccggtggcggttcggtggaggcggaagcggcggtggaggatcagac
aaaactcacacatgccca-3'

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65
66
67
68
69
70
71
72
73
74
75
76
77
78
79
80
81
82
83
84
85
86
87
88
89
90
91
92
93
94
95
96
97
98
99
100
101
102
103
104
105
106
107
108
109
110
111
112
113
114
115
116
117
118
119
120
121
122
123
124
125
126
127
128
129
130
131
132
133
134
135
136
137
138
139
140
141
142
143
144
145
146
147
148
149
150
151
152
153
154
155
156
157
158
159
160
161
162
163
164
165
166
167
168
169
170
171
172
173
174
175
176
177
178
179
180
181
182
183
184
185
186
187
188
189
190
191
192
193
194
195
196
197
198
199
200
201
202
203
204
205
206
207
208
209
210
211
212
213
214
215
216
217
218
219
220
221
222
223
224
225
226
227
228
229
230
231
232
233
234
235
236
237
238
239
240
241
242
243
244
245
246
247
248
249
250
251
252
253
254
255
256
257
258
259
260
261
262
263
264
265
266
267
268
269
270
271
272
273
274
275
276
277
278
279
280
281
282
283
284
285
286
287
288
289
290
291
292
293
294
295
296
297
298
299
300
301
302
303
304
305
306
307
308
309
310
311
312
313
314
315
316
317
318
319
320
321
322
323
324
325
326
327
328
329
330
331
332
333
334
335
336
337
338
339
340
341
342
343
344
345
346
347
348
349
350
351
352
353
354
355
356
357
358
359
360
361
362
363
364
365
366
367
368
369
370
371
372
373
374
375
376
377
378
379
380
381
382
383
384
385
386
387
388
389
390
391
392
393
394
395
396
397
398
399
400
401
402
403
404
405
406
407
408
409
410
411
412
413
414
415
416
417
418
419
420
421
422
423
424
425
426
427
428
429
430
431
432
433
434
435
436
437
438
439
440
441
442
443
444
445
446
447
448
449
450
451
452
453
454
455
456
457
458
459
460
461
462
463
464
465
466
467
468
469
470
471
472
473
474
475
476
477
478
479
480
481
482
483
484
485
486
487
488
489
490
491
492
493
494
495
496
497
498
499
500
501
502
503
504
505
506
507
508
509
510
511
512
513
514
515
516
517
518
519
520
521
522
523
524
525
526
527
528
529
530
531
532
533
534
535
536
537
538
539
540
541
542
543
544
545
546
547
548
549
550
551
552
553
554
555
556
557
558
559
560
561
562
563
564
565
566
567
568
569
570
571
572
573
574
575
576
577
578
579
580
581
582
583
584
585
586
587
588
589
590
591
592
593
594
595
596
597
598
599
600
601
602
603
604
605
606
607
608
609
610
611
612
613
614
615
616
617
618
619
620
621
622
623
624
625
626
627
628
629
630
631
632
633
634
635
636
637
638
639
640
641
642
643
644
645
646
647
648
649
650
651
652
653
654
655
656
657
658
659
660
661
662
663
664
665
666
667
668
669
670
671
672
673
674
675
676
677
678
679
680
681
682
683
684
685
686
687
688
689
690
691
692
693
694
695
696
697
698
699
700
701
702
703
704
705
706
707
708
709
710
711
712
713
714
715
716
717
718
719
720
721
722
723
724
725
726
727
728
729
730
731
732
733
734
735
736
737
738
739
740
741
742
743
744
745
746
747
748
749
750
751
752
753
754
755
756
757
758
759
760
761
762
763
764
765
766
767
768
769
770
771
772
773
774
775
776
777
778
779
780
781
782
783
784
785
786
787
788
789
790
791
792
793
794
795
796
797
798
799
800
801
802
803
804
805
806
807
808
809
810
811
812
813
814
815
816
817
818
819
820
821
822
823
824
825
826
827
828
829
830
831
832
833
834
835
836
837
838
839
840
841
842
843
844
845
846
847
848
849
850
851
852
853
854
855
856
857
858
859
860
861
862
863
864
865
866
867
868
869
870
871
872
873
874
875
876
877
878
879
880
881
882
883
884
885
886
887
888
889
890
891
892
893
894
895
896
897
898
899
900
901
902
903
904
905
906
907
908
909
910
911
912
913
914
915
916
917
918
919
920
921
922
923
924
925
926
927
928
929
930
931
932
933
934
935
936
937
938
939
940
941
942
943
944
945
946
947
948
949
950
951
952
953
954
955
956
957
958
959
960
961
962
963
964
965
966
967
968
969
970
971
972
973
974
975
976
977
978
979
980
981
982
983
984
985
986
987
988
989
990
991
992
993
994
995
996
997
998
999
1000
1001
1002
1003
1004
1005
1006
1007
1008
1009
1010
1011
1012
1013
1014
1015
1016
1017
1018
1019
1020
1021
1022
1023
1024
1025
1026
1027
1028
1029
1030
1031
1032
1033
1034
1035
1036
1037
1038
1039
1040
1041
1042
1043
1044
1045
1046
1047
1048
1049
1050
1051
1052
1053
1054
1055
1056
1057
1058
1059
1060
1061
1062
1063
1064
1065
1066
1067
1068
1069
1070
1071
1072
1073
1074
1075
1076
1077
1078
1079
1080
1081
1082
1083
1084
1085
1086
1087
1088
1089
1090
1091
1092
1093
1094
1095
1096
1097
1098
1099
1100
1101
1102
1103
1104
1105
1106
1107
1108
1109
1110
1111
1112
1113
1114
1115
1116
1117
1118
1119
1120
1121
1122
1123
1124
1125
1126
1127
1128
1129
1130
1131
1132
1133
1134
1135
1136
1137
1138
1139
1140
1141
1142
1143
1144
1145
1146
1147
1148
1149
1150
1151
1152
1153
1154
1155
1156
1157
1158
1159
1160
1161
1162
1163
1164
1165
1166
1167
1168
1169
1170
1171
1172
1173
1174
1175
1176
1177
1178
1179
1180
1181
1182
1183
1184
1185
1186
1187
1188
1189
1190
1191
1192
1193
1194
1195
1196
1197
1198
1199
1200
1201
1202
1203
1204
1205
1206
1207
1208
1209
1210
1211
1212
1213
1214
1215
1216
1217
1218
1219
1220
1221
1222
1223
1224
1225
1226
1227
1228
1229
1230
1231
1232
1233
1234
1235
1236
1237
1238
1239
1240
1241
1242
1243
1244
1245
1246
1247
1248
1249
1250
1251
1252
1253
1254
1255
1256
1257
1258
1259
1260
1261
1262
1263
1264
1265
1266
1267
1268
1269
1270
1271
1272
1273
1274
1275
1276
1277
1278
1279
1280
1281
1282
1283
1284
1285
1286
1287
1288
1289
1290
1291
1292
1293
1294
1295
1296
1297
1298
1299
1300
1301
1302
1303
1304
1305
1306
1307
1308
1309
1310
1311
1312
1313
1314
1315
1316
1317
1318
1319
1320
1321
1322
1323
1324
1325
1326
1327
1328
1329
1330
1331
1332
1333
1334
1335
1336
1337
1338
1339
1340
1341
1342
1343
1344
1345
1346
1347
1348
1349
1350
1351
1352
1353
1354
1355
1356
1357
1358
1359
1360
1361
1362
1363
1364
1365
1366
1367
1368
1369
1370
1371
1372
1373
1374
1375
1376
1377
1378
1379
1380
1381
1382
1383
1384
1385
1386
1387
1388
1389
1390
1391
1392
1393
1394
1395
1396
1397
1398
1399
1400
1401
1402
1403
1404
1405
1406
1407
1408
1409
1410
1411
1412
1413
1414
1415
1416
1417
1418
1419
1420
1421
1422
1423
1424
1425
1426
1427
1428
1429
1430
1431
1432
1433
1434
1435
1436
1437
1438
1439
1440
1441
1442
1443
1444
1445
1446
1447
1448
1449
1450
1451
1452
1453
1454
1455
1456
1457
1458
1459
1460
1461
1462
1463
1464
1465
1466
1467
1468
1469
1470
1471
1472
1473
1474
1475
1476
1477
1478
1479
1480
1481
1482
1483
1484
1485
1486
1487
1488
1489
1490
1491
1492
1493
1494
1495
1496
1497
1498
1499
1500
1501
1502
1503
1504
1505
1506
1507
1508
1509
1510
1511
1512
1513
1514
1515
1516
1517
1518
1519
1520
1521
1522
1523
1524
1525
1526
1527
1528
1529
1530
1531
1532
1533
1534
1535
1536
1537
1538
1539
1540
1541
1542
1543
1544
1545
1546
1547
1548
1549
1550
1551
1552
1553
1554
1555
1556
1557
1558
1559
1560
1561
1562
1563
1564
1565
1566
1567
1568
1569
1570
1571
1572
1573
1574
1575
1576
1577
1578
1579
1580
1581
1582
1583
1584
1585
1586
1587
1588
1589
1590
1591
1592
1593
1594
1595
1596
1597
1598
1599
1600
1601
1602
1603
1604
1605
1606
1607
1608
1609
1610
1611
1612
1613
1614
1615
1616
1617
1618
1619
1620
1621
1622
1623
1624
1625
1626
1627
1628
1629
1630
1631
1632
1633
1634
1635
1636
1637
1638
1639
1640
1641
1642
1643
1644
1645
1646
1647
1648
1649
1650
1651
1652
1653
1654
1655
1656
1657
1658
1659
1660
1661
1662
1663
1664
1665
1666
1667
1668
1669
1670
1671
1672
1673
1674
1675
1676
1677
1678
1679
1680
1681
1682
1683
1684
1685
1686
1687
1688
1689
1690
1691
1692
1693
1694
1695
1696
1697
1698
1699
1700
1701
1702
1703
1704
1705
1706
1707
1708
1709
1710
1711
1712
1713
1714
1715
1716
1717
1718
1719
1720
1721
1722
1723
1724
1725
1726
1727
1728
1729
1730
1731
1732
1733
1734
1735
1736
1737
1738
1739
1740
1741
1742
1743
1744
1745
1746
1747
1748
1749
1750
1751
1752
1753
1754
1755
1756
1757
1758
1759
1760
1761
1762
1763
1764
1765
1766
1767
1768
1769
1770
1771
1772
1773
1774
1775
1776
1777
1778
1779
1780
1781
1782
1783
1784
1785
1786
1787
1788
1789
1790
1791
1792
1793
1794
1795
1796
1797
1798
1799
1800
1801
1802
1803
1804
1805
1806
1807
1808
1809
1810
1811
1812
1813
1814
1815
1816
1817
1818
1819
1820
1821
1822
1823
1824
1825
1826
1827
1828
1829
1830
1831
1832
1833
1834
1835
1836
1837
1838
1839
1840
1841
1842
1843
1844
1845
1846
1847
1848
1849
1850
1851
1852
1853
1854
1855
1856
1857
1858
1859
1860
1861
1862
1863
1864
1865
1866
1867
1868
1869
1870
1871
1872
1873
1874
1875
1876
1877
1878
1879
1880
1881
1882
1883
1884
1885
1886
1887
1888
1889
1890
1891
1892
1893
1894
1895
1896
1897
1898
1899
1900
1901
1902
1903
1904
1905
1906
1907
1908
1909
1910
1911
1912
1913
1914
1915
1916
1917
1918
1919
1920
1921
1922
1923
1924
1925
1926
1927
1928
1929
1930
1931
1932
1933
1934
1935
1936
1937
1938
1939
1940
1941
1942
1943
1944
1945
1946
1947
1948
1949
1950
1951
1952
1953
1954
1955
1956
1957
1958
1959
1960
1961
1962
1963
1964
1965
1966
1967
1968
1969
1970
1971
1972
1973
1974
1975
1976
1977
1978
1979
1980
1981
1982
1983
1984
1985
1986
1987
1988
1989
1990
1991
1992
1993
1994
1995
1996
1997
1998
1999
2000
2001
2002
2003
2004
2005
2006
2007
2008
2009
2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
2026
2027
2028
2029
2030
2031
2032
2033
2034
2035
2036
2037
2038
2039
2040
2041
2042
2043
2044
2045
2046
2047
2048
2049
2050
2051
2052
2053
2054
2055
2056
2057
2058
2059
2060
2061
2062
2063
2064
2065
2066
2067
2068
2069
2070
2071
2072
2073
2074
2075
2076
2077
2078
2079
2080
2081
2082
2083
2084
2085
2086
2087
2088
2089
2090
2091
2092
2093
2094
2095
2096
2097
2098
2099
2100
2101
2102
2103
2104
2105
2106
2107
2108
2109
2110
2111
2112
2113
2114
2115
2116
2117
2118
2119
2120
2121
2122
2123
2124
2125
2126
2127
2128
2129
2130
2131
2132
2133
2134
2135
2136
2137
2138
2139
2140
2141
2142
2143
2144
2145
2146
2147
2148
2149
2150
2151
2152
2153
2154
2155
2156
2157
2158
2159
2160
2161
2162
2163
2164
2165
2166
2167
2168
2169
2170
2171
2172
2173
2174
2175
2176
2177
2178
2179
2180
2181
2182
2183
2184
2185
2186
2187
2188
2189